Anti-CYP2C9 Antibody

CYP2C9 is a hepatic cytochrome P450 enzyme central to the oxidative metabolism of widely prescribed drugs, including the anticoagulant warfarin, the anticonvulsant phenytoin, and several non-steroidal anti-inflammatory agents. This unconjugated rabbit polyclonal antibody is raised by Antibodies.com against CYP2C9 and has been validated for western blot, immunohistochemistry, and immunofluorescence applications on human tissue. The reagent is supplied as a 100 µl vial at 1 mg/ml in PBS containing 0.1% sodium azide and 50% glycerol as a stabilizing cryoprotectant, simplifying handling at the bench and reducing freeze-thaw stress on working aliquots.

Investigators studying pharmacogenomic variation, hepatic drug clearance, or warfarin dosing sensitivity rely on this reagent to assess CYP2C9 protein abundance in liver biopsies, tumor microarrays, and cultured hepatocyte models. The unconjugated format gives researchers flexibility to pair the antibody with their preferred HRP-, biotin-, or fluorophore-conjugated secondary reagent. Sodium azide in the buffer means it should not be added to live-cell labeling reactions, and downstream HRP-based detection can be protected by azide quench steps where needed. Researchers should titrate the antibody empirically for their fixative, antigen retrieval, and detection method, and Antibodies.com stocks related polyclonal and monoclonal options for parallel experiments, isotype controls, and species-specific secondary antibodies.